Nkarta Inc. (NKTX): Prakiraan wutah bathi kanggo taun ngarep

NKTX (nkartatx.com) - tandha merek perusahaan

Nkarta, Inc. (NKTX) is an innovative biotech firm attracting leading biologists to combat oncology. The company is developing a safe NK-cell-based therapy against leukemia and solid tumors. The projected EPS growth rate for next year on the GURU.Markets chart shows that the current figure is 18.80. The business valuation is based on allogeneic technology patents, the success of which is determined by early clinical trial results.

Nkarta Corp (NKTX): Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep saka 04.07.2022 nganti 16.11.2026

Rincian analitis lan laporan data perusahaan Nkarta Corp (NKTX)

- rega lan prakiraan konsensus rega:
Pambiji fundamental perusahaan:Nkarta, Inc.
Produk dadi Nkarta Inc.

Nkarta, Inc. (NKTX) is developing cell therapy through manufacturing partnerships, avoiding costly merger deals. Analyzing this chart of expected EPS growth over 12 months, an investor can see the professional analysts' consensus forecast for future profitability. This metric measures earnings per share dynamics, assessing the business's ability to generate cash flow in the coming year. Extreme values here signal inflated expectations, which increases the risk of a capital correction.